EP4159734A4 - Fluorpyrrolopyridinverbindung und anwendung davon - Google Patents

Fluorpyrrolopyridinverbindung und anwendung davon Download PDF

Info

Publication number
EP4159734A4
EP4159734A4 EP21813936.8A EP21813936A EP4159734A4 EP 4159734 A4 EP4159734 A4 EP 4159734A4 EP 21813936 A EP21813936 A EP 21813936A EP 4159734 A4 EP4159734 A4 EP 4159734A4
Authority
EP
European Patent Office
Prior art keywords
fluoropyrrolopyridine
compound
application
fluoropyrrolopyridine compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21813936.8A
Other languages
English (en)
French (fr)
Other versions
EP4159734A1 (de
Inventor
Kun FANG
Shuhui Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Life Fountain Biotech Co ltd
Original Assignee
Wuxi Life Fountain Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Life Fountain Biotech Co Ltd filed Critical Wuxi Life Fountain Biotech Co Ltd
Publication of EP4159734A1 publication Critical patent/EP4159734A1/de
Publication of EP4159734A4 publication Critical patent/EP4159734A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21813936.8A 2020-05-29 2021-05-26 Fluorpyrrolopyridinverbindung und anwendung davon Pending EP4159734A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010478432 2020-05-29
CN202110139687 2021-02-01
PCT/CN2021/096143 WO2021238999A1 (zh) 2020-05-29 2021-05-26 氟代吡咯并吡啶类化合物及其应用

Publications (2)

Publication Number Publication Date
EP4159734A1 EP4159734A1 (de) 2023-04-05
EP4159734A4 true EP4159734A4 (de) 2024-06-19

Family

ID=78745589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21813936.8A Pending EP4159734A4 (de) 2020-05-29 2021-05-26 Fluorpyrrolopyridinverbindung und anwendung davon

Country Status (7)

Country Link
US (1) US20230212165A1 (de)
EP (1) EP4159734A4 (de)
JP (1) JP7418051B2 (de)
KR (1) KR20230012586A (de)
CN (1) CN115667258B (de)
AU (1) AU2021282122B2 (de)
WO (1) WO2021238999A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378799A1 (en) * 2019-06-06 2022-12-01 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor
WO2021238999A1 (zh) * 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
MX2020000386A (es) 2017-07-13 2020-08-06 Univ Texas Inhibidores heterociclicos de la cinasa atr.
EP3668839B1 (de) * 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclische inhibitoren der atr-kinase
CA3074719A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc Substituted pyrrolopyridines as atr inhibitors
EP3753937B1 (de) * 2018-02-07 2024-01-10 Wuxi Biocity Biopharmaceutics Co., Ltd. Atr-inhibitor und anwendung davon
WO2021238999A1 (zh) * 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
US20230212165A1 (en) 2023-07-06
JP7418051B2 (ja) 2024-01-19
AU2021282122A1 (en) 2023-02-09
WO2021238999A1 (zh) 2021-12-02
KR20230012586A (ko) 2023-01-26
CN115667258A (zh) 2023-01-31
AU2021282122B2 (en) 2023-09-21
CN115667258B (zh) 2024-07-12
EP4159734A1 (de) 2023-04-05
JP2023526490A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
EP4101852A4 (de) Pyridopyrimidinonverbindung und anwendung davon
EP4105211A4 (de) Pyrimidoheterocyclische verbindungen und anwendung davon
EP4132529A4 (de) Verbindungen und verwendungen davon
EP4096664A4 (de) Verbindungen und verwendungen davon
EP3917526A4 (de) Verbindungen und verwendungen davon
EP3917934A4 (de) Verbindungen und verwendungen davon
EP3992291A4 (de) Neue verbindung und anwendung davon
EP4096667A4 (de) Verbindungen und verwendungen davon
EP3917517A4 (de) Verbindungen und verwendungen davon
EP3917529A4 (de) Verbindungen und verwendungen davon
EP4096651A4 (de) Verbindungen und verwendungen davon
EP4159734A4 (de) Fluorpyrrolopyridinverbindung und anwendung davon
EP4096668A4 (de) Verbindungen und verwendungen davon
EP4097096A4 (de) Verbindungen und verwendungen davon
EP3917527A4 (de) Verbindungen und verwendungen davon
EP4151277A4 (de) Substituierte piperidinverbindung und anwendung davon
EP3892621A4 (de) Haloallylaminverbindungen und anwendung davon
EP3998254A4 (de) 2-aminopyrimidinverbindung und anwendung davon
EP4151636A4 (de) Pyrrolidinverbindung und verwendung davon
EP3941908A4 (de) Verbindungen und verwendungen davon
EP4166542A4 (de) Bicyclische verbindung und anwendung davon
EP3978468A4 (de) Verbindung und zusammensetzung
EP4019521A4 (de) Azaheteroarylverbindung und anwendung davon
EP4006048A4 (de) Neuartiges mikropeptid hmmw und seine verwendung
EP3911322A4 (de) Verbindungen und verwendungen davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WUXI LIFE FOUNTAIN BIOTECH CO., LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20240517

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240514BHEP

Ipc: A61K 31/437 20060101ALI20240514BHEP

Ipc: C07D 471/04 20060101AFI20240514BHEP